arrow-leftarrowbookmarkcategorychatcheckclosedots-with-opacitydotsdown-chevronfacebookhero-lefthero-righthvh-logo-whitelinkedinplaceholderrelated-findingssearchtwitter
Evidence

Analysis of Real-World Oral Prednisone Usage in Patients with Dermatomyositis Supports the Unmet Need for Additional Corticosteroid-Sparing Agents

Date: 07/12/2019

Poster presented at: Global Conference on Myositis

Location and date: Potomac, MD; May 5-8, 2017

Authors: Tara Grabowsky, Jim Baker, Kirstin Lees, Cody Garges, Oodaye Shukla, Faith DeFreitas, Joanna Horobin

Objectives:

  • The objective of the study was to assess the real-world use of oral prednisone via a closed commercial and Medicare supplemental claims database to understand the unmet need for new corticosteroid-sparing agents for patients with dermatomyositis. 
  • Statistical analysis was performed on the defined patient cohort using Anaconda Python.

Conclusions:

  • Approximately half of DM patients were prescribed high or low dose prednisone for 120 days or longer.
  • The use of high dose prednisone was required to treat DM patients throughout all phases of their illness (pre-diagnosis, at diagnosis, and up to 5 years post diagnosis).
  • One quarter of DM patients were prescribed high dose prednisone for prolonged periods of time.
  • With high numbers of DM patients on chronic and high dose prednisone, the need for medications that have a steroid-sparing effect in the DM population is evident.
    • These data support the urgency to develop medications that have a potential steroid-sparing effect to reduce the number of patients who could experience harmful steroid-related side effects.
  • Future analyses should evaluate the incidence of corticosteroid-related adverse events and the limitations of currently used corticosteroid-sparing medications in the DM population.

Analysis of Real-World Oral Prednisone Usage in Patients with Dermatomyositis Supports the Unmet Need for Additional Corticosteroid-Sparing Agents

VIEW THE POSTER